Extended-spectrum β-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests

Infect Control Hosp Epidemiol. 2012 Aug;33(8):853-5. doi: 10.1086/666632. Epub 2012 Jun 11.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Cefepime
  • Cefuroxime / pharmacology*
  • Cephalosporins / pharmacology*
  • Escherichia coli / drug effects*
  • Escherichia coli / metabolism
  • Humans
  • Klebsiella pneumoniae / drug effects*
  • Klebsiella pneumoniae / metabolism
  • Microbial Sensitivity Tests
  • Penicillanic Acid / analogs & derivatives
  • Penicillanic Acid / pharmacology
  • Piperacillin / pharmacology
  • Piperacillin, Tazobactam Drug Combination
  • beta-Lactamases / biosynthesis

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • Piperacillin, Tazobactam Drug Combination
  • Cefepime
  • Penicillanic Acid
  • beta-Lactamases
  • Cefuroxime
  • Piperacillin